MiNK Therapeutics Publishes Details of Complete Remission in Metastatic Testicular Cancer Following Allogeneic iNKT Cell Therapy
DENVER, Colo., Jul 11, 2025 (247marketnews.com)- MiNK’s (NASDAQ:INKT) publication of another landmark case in Nature’s Oncogene describing a complete and durable remission in a patient with metastatic, treatment‑refractory testicular cancer, following treatment with agenT‑797, MiNK’s allogeneic iNKT cell therapy.
The published case, titled Salvage therapy with allogeneic invariant natural killer T cells in a heavily pre‑treated germ cell tumor, describes a patient within MiNK’s NCT05108623 trial who achieved “Complete remission after failure on platinum‑based chemotherapy, autologous stem cell transplant, and multiple ICIs (anti–PD‑1, anti–CTLA‑4, and anti–TIGIT)”. The patient received a single infusion of agenT‑797 alongside nivolumab and ultimately achieved complete clinical, radiologic, and biochemical remission, with no evidence of disease over two years later. Donor iNKT cells were detectable up to six months post‑infusion, and treatment was well‑tolerated with no cytokine release syndrome (CRS) or graft‑versus‑host disease (GVHD) detectable.
Benjamin Garmezy, Assistant Director of Genitourinary Research for Sarah Cannon Research Institute at SCRI Oncology Partners, said, “This case exemplifies the powerful potential of iNKT cells in treating even the most challenging cancers. We observed a remarkable response in a patient who had exhausted standard and experimental treatments, offering compelling evidence to further pursue clinical studies of iNKT cell therapies in solid tumors.”
These findings add to a growing body of clinical evidence supporting the potential of agenT‑797 in solid tumors. At the 2025 inaugural AACR Immuno‑Oncology meeting, MiNK presented data from its Phase 2 trial in second‑line gastric cancer showing immune activation, increased tumor infiltration, and early signals of tumor control in patients previously refractory to checkpoint inhibitors. Extended survival beyond 12 months was observed in several patients, an uncommon outcome in this setting.
A separate peer‑reviewed case report in Oncogene described a patient with metastatic gastric cancer achieving a 42% tumor reduction and more than nine months of progression‑free survival following a single infusion of agenT‑797 in combination with nivolumab. Together, these data highlight the potential for agenT‑797 to reshape the tumor microenvironment and deliver durable clinical activity in heavily pre‑treated, immunotherapy‑resistant cancers.
MiNK’s Phase 2 gastric cancer trial (NCT06251973) is actively enrolling, with additional readouts expected over the coming months.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com